197 related articles for article (PubMed ID: 34050985)
21. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Marín LA; Díaz MG; San Miguel JF; Sanz RG
Ann Hematol; 2013 Jan; 92(1):97-100. PubMed ID: 22956183
[TBL] [Abstract][Full Text] [Related]
22. MRD in multiple myeloma: more questions than answers?
Moreau P; Zamagni E
Blood Cancer J; 2017 Dec; 7(12):639. PubMed ID: 29209089
[No Abstract] [Full Text] [Related]
23. Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition.
Pianko MJ; Devlin SM; Littmann ER; Chansakul A; Mastey D; Salcedo M; Fontana E; Ling L; Tavitian E; Slingerland JB; Slingerland AE; Clurman A; Gomes ALC; Taur Y; Pamer EG; Peled JU; van den Brink MRM; Landgren O; Lesokhin AM
Blood Adv; 2019 Jul; 3(13):2040-2044. PubMed ID: 31289031
[TBL] [Abstract][Full Text] [Related]
24. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.
Rasmussen T; Poulsen TS; Honoré L; Johnsen HE
Exp Hematol; 2000 Sep; 28(9):1039-45. PubMed ID: 11008016
[TBL] [Abstract][Full Text] [Related]
25. Significance of bone marrow biopsy in the multiple myeloma.
Bartl R; Burkhardt R; Gierster P; Sandel P; Fateh-Moghadam A
Bibl Haematol; 1978; 45():81-6. PubMed ID: 747638
[No Abstract] [Full Text] [Related]
26. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
Landgren O; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
[TBL] [Abstract][Full Text] [Related]
27. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
Rawstron AC; de Tute RM; Haughton J; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
[TBL] [Abstract][Full Text] [Related]
28. Significance of analyzing circulating plasma cells in multiple myeloma: differences from measuring minimal residual diseases in bone marrow.
Kim SM; Lee Y; Jeong D; Yun J; Yoon SS; Hwang SM; Lee N; Lee DS
Leuk Lymphoma; 2022 Feb; 63(2):487-490. PubMed ID: 34727831
[No Abstract] [Full Text] [Related]
29. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
30. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation.
Sukpanichnant S; Cousar JB; Leelasiri A; Graber SE; Greer JP; Collins RD
Hum Pathol; 1994 Mar; 25(3):308-18. PubMed ID: 8150462
[TBL] [Abstract][Full Text] [Related]
32. Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers.
Welterlin V; Debecker A; Tschieb D; Zanetti C; Lange W; Hénon PR
J Hematother Stem Cell Res; 2000 Dec; 9(6):983-91. PubMed ID: 11177613
[TBL] [Abstract][Full Text] [Related]
33. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma.
Alonso R; Cedena MT; Gómez-Grande A; Ríos R; Moraleda JM; Cabañas V; Moreno MJ; López-Jiménez J; Martín F; Sanz A; Valeri A; Jiménez A; Sánchez R; Lahuerta JJ; Martínez-López J
Am J Hematol; 2019 Aug; 94(8):853-861. PubMed ID: 31074033
[TBL] [Abstract][Full Text] [Related]
34. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma.
Cavo M; Terragna C; Martinelli G; Ronconi S; Zamagni E; Tosi P; Lemoli RM; Benni M; Pagliani G; Bandini G; Tura S
Blood; 2000 Jul; 96(1):355-7. PubMed ID: 10891473
[TBL] [Abstract][Full Text] [Related]
35. Multiple myeloma: Current advances and future directions.
Ola Landgren C
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101155. PubMed ID: 32139007
[No Abstract] [Full Text] [Related]
36. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
38. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
39. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
[TBL] [Abstract][Full Text] [Related]
40. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting.
Corradini P; Voena C; Astolfi M; Ladetto M; Tarella C; Boccadoro M; Pileri A
Blood; 1995 Mar; 85(6):1596-602. PubMed ID: 7888677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
